# US 2001/0043934 A1 · Formulations for amylin agonist peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0043934 A1
- Document ID: US20010043934A1
- Status: Published application
- Kind: A1
- Application number: 09/005,262
- Filed: 1998-01-09
- Published: 2001-11-22
- Earliest claimed: 1997-01-08
- Assignees: Amylin Pharmaceuticals, Inc.
- Inventors: JAMES L'ITALIEN; SHANKAR MUSUNURI; KALE RUBY
- Web page: https://patentgrep.com/patent/US20010043934A1

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is concerned with a pharmaceutical formulation in a container, for example, a vial, prefilled cartridge, prefilled syringe or disposable pen, comprising approximately 0.01 to about 0.5% (w/v) amylin agonist, preferably pramlintide, in an aqueous system along with approximately 0.02 to about 0.5% (w/v) of an acetate, phosphate, citrate, or glutamate buffer to a pH of the final composition of approximately 3.0 to about 6.0 as well as approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol tonicifier; and, optionally, approximately 0.005 to 1.0% (w/v) of a preservative selected from the group consisting of m-cresol, benzyl alcohol, parabens and phenol. These formulations maintain stability upon storage under refrigerated or room temperature conditions. Such formulations can be further combined with insulin in the same syringe for administration to a patient.

## Claims

### Claim 1

A liquid, pharmaceutical formulation comprising about 0.01 to about 0.5% (w/v) of an amylin agonist, about 1.0 to about 10% (w/v) of a carbohydrate or a polyhydric alcohol, and about 0.02 to about 0.5% (w/v) of an acetate, phosphate, citrate or glutamate buffer, and which has a pH about 3.0 to about 6.0.

### Claim 2 (depends on 1)

The liquid, pharmaceutical formulation of claim 1 which is substantially isotonic.

### Claim 3 (depends on 1)

The liquid, pharmaceutical formulation of claim 1 which further comprises a preservative.

### Claim 4 (depends on 3)

The liquid, pharmaceutical formulation of claim 3 wherein said preservative is selected from the group consisting of m-cresol, benzyl alcohol, methyl, ethyl, propyl and butyl parabens and phenol.

### Claim 5 (depends on 1, 2, 3, 4)

The liquid, pharmaceutical formulation of any of claims 1-4, wherein said amylin agonist is pramlintide.

### Claim 6 (depends on 1, 2, 3, 4)

The liquid, pharmaceutical formulation of any of claims 1-4, wherein said polyhydric alcohol is selected from the group consisting of mannitol, sorbitol, inositol, glycerol, xylitol, propylene/ethylene glycol copolymer, PEG 8000, PEG 400, PEG 4000, PEG 200, PEG 1450 or PEG 3350.

### Claim 7 (depends on 1, 2, 3, 4)

The liquid, pharmaceutical formulation of any of claims 1-4, wherein said polyhydric alcohol is mannitol.

### Claim 8 (depends on 1, 2, 3, 4)

The liquid, pharmaceutical formulation of any of claims 1-4, wherein said carbohydrate is selected from the group consisting of mannose, ribose, trehalose, maltose, glycerol, inositol and lactose.

### Claim 9 (depends on 1, 2, 3, 4)

The liquid, pharmaceutical formulation of any of claims 1-4, wherein said buffer is an acetate buffer.

### Claim 10 (depends on 1, 2, 3, 4)

The liquid, pharmaceutical formulation of any of claims 1-4, wherein the pH of said formulation is about 3.5 to about 5.0.

### Claim 11 (depends on 1, 2, 3, 4)

The liquid, pharmaceutical formulation of any of claims 1-4, wherein the pH of said formulation is about 3.8 to about 4.2.

### Claim 12 (depends on 1, 2, 3, 4)

The liquid, pharmaceutical formulation of any of claims 1-4, wherein said preservative is approximately at least about 0.15% (w/v) of m-cresol.

### Claim 13 (depends on 1, 2, 3, 4)

The liquid, pharmaceutical formulation of any of claims 1-4, wherein said preservative is approximately about 0.1 to about 0.3 (w/v) of m-cresol.

### Claim 14 (depends on 1, 2, 3, 4)

The liquid, pharmaceutical formulation of any of claims 1-4, wherein said formulation further comprises a surfactant.

### Claim 15 (depends on 1, 2, 3, 4)

The liquid, pharmaceutical formulation of any of claims 1-4, wherein said surfactant is selected from the group consisting of polyoxyethylene (20) sorbitan monooleate, 3-[(3-cholamidopropyl) dimethylanmonio] 1-propanl sulfonate, polyoxyethylene (23) lauryl ether, poloxamer or a non-ionic surfactant.

### Claim 16

A formulation comprising an amylin agonist which is biologically active, has a reduced tendency to form aggregates in water or at a pressure of greater than 2 psi compared to human amylin, and has a reduced tendency to precipitate in the presence of NaCl compared to human amylin, admixed with one or more compounds which reduce loss of activity of said amylin agonist, in an amylin specific receptor binding assay or bioactivity assay or HPLC assay compared to a composition consisting of said amylin agonist in phosphate-buffered saline or saline, said compounds comprising a tonicity agent and a buffer, said tonicity agent being provided in an amount between 0.01% and 10% and said formulation having a pH of about 3.0 to about 6.0.

### Claim 17 (depends on 14)

The formulation of claim 14, further comprising a preservative

### Claim 18

A method for treating a patient with pramlintide, and insulin, said method comprising admixing a formulation of pramlintide with insulin and administering the mixture of said formulation and insulin to a patient in need of such treatment, wherein said formulation comprising a tonicifier, a buffer and a preservative, said tonicifier comprising approximately 1.0 to 10% (w/v) of a carbohydrate or a polyhydric alcohol, said buffer comprising approximately 0.02 to 0.5% (w/v) of an acetate, phosphate, citrate or glutamate buffer which allows a pH of the final formulation of approximately 3.0 to 6.0, and said preservative comprising a compound selected from the group consisting of m-cresol, benzyl alcohol, methyl, ethyl, propyl and butyl parabens and phenol, and wherein said pramlintide comprises about 0.01 to about 0.5% (w/v) of the formulation.

### Claim 19

A commercial package containing a liquid pharmaceutical formulation containing pramlintide, for parenteral administration to a patient, said package comprising a borosilicate glass vial having an open end, a stopper intended for multiuse which is compatible with the amylin and/or amylin agonist, fixed in the open end of the vial, an aluminum band to retain the stopper in the far end of the vial wherein said liquid pharmaceutical formulation comprises a tonicifier, a buffer and a preservative, said tonicifier comprising 1.0 approximately to 10% (w/v) of a carbohydrate or a polyhydric alcohol, said buffer comprising approximately 0.02 to 0.5% (w/v) of an acetate, phosphate or glutamate buffer which allows a pH of the final formulation of approximately 3.0 to 6.0, and said preservative is selected from the group consisting of m-cresol, benzyl alcohol, methyl and ethyl parabens and phenol and said pramlintide approximately 0.01 to 0.5% (w/v) of the formulation.

### Claim 20

A commercial package containing a liquid pharmaceutical formulation containing pramlintide, for parenteral administration to a patient, said package comprising a cartridge suitable for use in a pen injector wherein said liquid pharmaceutical formulation comprises a stabilizer, a buffer and a preservative, said stabilizer comprising 1.0 approximately to 10% (w/v) of a carbohydrate or a polyhydric alcohol, said buffer comprising approximately 0.02 to 0.5% (w/v) of an acetate, phosphate, citrate or glutamate buffer which allows a pH of the final formulation of approximately 3.0 to 6.0, and said preservative is selected from the group consisting of m-cresol, benzyl alcohol, methyl and ethyl parabens and phenol and said pramlintide is approximately 0.01 to 0.5% (w/v) of the formulation.

### Claim 21

A composition which comprises about 0.01 to about 0.5% (w/v) of pramlintide, about 1.0 to about 10% (w/v) of mannitol, and about 0.02 to about 0.5% (w/v) of an acetate buffer.

### Claim 22 (depends on 21)

The composition of claim 21 which is a liquid.

### Claim 23 (depends on 21)

The composition of claim 21 which further comprises about 0.1 to about 0.3% (w/v) of m-cresol.

### Claim 24 (depends on 23)

The composition of claim 23 which is a liquid.

### Claim 25 (depends on 22, 24)

The composition of either of claims 22 or 24 which has a pH of from about 3.0 to about 6.0.

### Claim 26 (depends on 22, 24)

The composition of either of claims 22 or 24 which has a pH of from about 3.5 to about 5.0.

### Claim 27 (depends on 22, 24)

The composition of either of claims 22 or 24 which has a pH of from about 3.8 to about 4.2.

### Claim 28 (depends on 21)

The composition of claim 21 which is lyophilized.

### Claim 29

A composition which comprises about 0.01 to about 0.5% (w/v) of pramlintide and about 0.02 to about 0.5% (w/v) of an acetate buffer.

### Claim 30 (depends on 29)

The composition of claim 29 which is a liquid.

### Claim 31 (depends on 29)

The composition of claim 29 which is lyophilized.
